Altamira Therapeutics Management
Management criteria checks 3/4
Altamira Therapeutics' CEO is Thomas Meyer, appointed in Apr 2003, has a tenure of 21.92 years. total yearly compensation is $778.61K, comprised of 55.9% salary and 44.1% bonuses, including company stock and options. directly owns 0.43% of the company’s shares, worth $2.00K. The average tenure of the management team and the board of directors is 2.8 years and 7.5 years respectively.
Key information
Thomas Meyer
Chief executive officer
US$778.6k
Total compensation
| CEO salary percentage | 55.9% |
| CEO tenure | 21.9yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.8yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID
Sep 13Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio
Aug 30Altamira starts development program for potential arthritis therapy
Jul 25Altamira announces peer-reviewed publication on mRNA delivery platform
Jul 19Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform
Jul 12Auris Medical shares rise on OligoPhore Lymphoma study results
Jun 21Auris Medical starts preparations for COVID-19 trial with Bentrio in India
Jun 01Auris Medical updates on pollen challenge study for nasal spray
May 10Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?
Dec 09
Auris Medical prices $8M direct equity offering, stock -22%
Dec 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$8m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$779k | US$435k | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$16m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$690k | US$396k | -US$20m |
| Sep 30 2022 | n/a | n/a | -US$23m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$1m | US$401k | -US$7m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$13m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$741k | US$411k | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$6m |
| Dec 31 2019 | US$606k | US$376k | -US$7m |
| Sep 30 2019 | n/a | n/a | -US$9m |
| Jun 30 2019 | n/a | n/a | -US$11m |
| Mar 31 2019 | n/a | n/a | -US$12m |
| Dec 31 2018 | US$636k | US$370k | -US$12m |
Compensation vs Market: Thomas's total compensation ($USD778.61K) is about average for companies of similar size in the US market ($USD640.24K).
Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.
CEO
Thomas Meyer (56 yo)
21.9yrs
Tenure
US$778,611
Compensation
Dr. Thomas Meyer, Ph.D. Founded Altamira Therapeutics Ltd. (formerly known as Auris Medical Holding Ltd.) (formerly known as Auris Medical Holding AG) in April 2003 and serves as Managing Director, Chairma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.9yrs | US$778.61k | 0.43% $ 2.0k | |
| Chief Financial Officer | 3.3yrs | no data | 0.00069% $ 3.2 | |
| Chief Operating Officer | 2.2yrs | no data | no data | |
| Chief Scientific Adviser | 2.2yrs | no data | no data |
2.8yrs
Average Tenure
61yo
Average Age
Experienced Management: CYTO.F's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.9yrs | US$778.61k | 0.43% $ 2.0k | |
| Independent Non-Executive Director | 7yrs | US$59.34k | 0.0060% $ 27.8 | |
| Independent Non-Executive Director | 7.9yrs | US$59.34k | 0.0060% $ 27.9 | |
| Director | less than a year | no data | no data |
7.5yrs
Average Tenure
59yo
Average Age
Experienced Board: CYTO.F's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/06 23:00 |
| End of Day Share Price | 2025/03/06 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Altamira Therapeutics Ltd. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hunter Diamond | Diamond Equity Research LLC |
| Maxim Jacobs | Edison Investment Research |
| Christopher Howerton | Jefferies LLC |